AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
Phase 2
Terminated
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Biological: BenralizumabBiological: Placebo and Benralizumab
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 159
- Registration Number
- NCT04612725
- Locations
- 🇪🇸
Research Site, Manises, Spain
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
Phase 3
Terminated
- Conditions
- Bullous Pemphigoid
- Interventions
- Biological: Placebo
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 67
- Registration Number
- NCT04612790
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
Phase 2
Completed
- Conditions
- Coronary Heart Disease (CHD)
- Interventions
- Biological: Placebo
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 423
- Registration Number
- NCT04610892
- Locations
- 🇬🇧
Research Site, Wythenshawe, United Kingdom
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: BGF MDI 320/28.8/9.6 μgDrug: BGF MDI 320/14.4/9.6 μgDrug: BFF MDI 320/9.6 μgDrug: BFF pMDI 320/9 μg
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2274
- Registration Number
- NCT04609878
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: BFF MDI 320/9.6 μgDrug: BGF MDI 320/28.8/9.6 μgDrug: BFF pMDI 320/9 μgDrug: BGF MDI 320/14.4/9.6 μg
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2187
- Registration Number
- NCT04609904
- Locations
- 🇬🇧
Research Site, Rhyl, United Kingdom
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT04606771
- Locations
- 🇻🇳
Research Site, Ho Chi Minh city, Vietnam
A Study of CIN-107 in Adults With Primary Aldosteronism
Phase 2
Completed
- Conditions
- Primary AldosteronismHyperaldosteronism
- Interventions
- Drug: CIN-107 2 mg dosingDrug: CIN-107 4 mg dosingDrug: CIN-107 8 mg dosing
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT04605549
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
Phase 2
Terminated
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: Placebo / BenralizumabBiological: Benralizumab
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 194
- Registration Number
- NCT04605094
- Locations
- 🇪🇸
Research Site, Manises, Spain
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment C
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT04600505
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- Diffuse Large B Cell LymphomaB-cell Non Hodgkin LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma
- Interventions
- Drug: AZD0486 IV
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 317
- Registration Number
- NCT04594642
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath